HC Wainwright Reaffirms “Buy” Rating for Alimera Sciences (NASDAQ:ALIM)

HC Wainwright reiterated their buy rating on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Alimera Sciences’ Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings […]

Leave a Reply

Your email address will not be published.

Previous post Alibaba Group (NYSE:BABA) Price Target Raised to $103.00
Next post DA Davidson Boosts Arcosa (NYSE:ACA) Price Target to $110.00